Overview

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Status:
Completed

Trial end date:
2018-02-08

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Endothelial Growth Factors
Everolimus
Lenvatinib
Sirolimus